Difference between revisions of "Part:BBa K1800003"
(4 intermediate revisions by 2 users not shown) | |||
Line 2: | Line 2: | ||
<partinfo>BBa_K1800003 short</partinfo> | <partinfo>BBa_K1800003 short</partinfo> | ||
<div style="text-align:justify;"> | <div style="text-align:justify;"> | ||
− | Cannabidiolic-acid (CBDA) synthase is the enzyme that catalyzes the oxidative cyclization of cannabigerolic-acid(CBGA) into cannabidiolic acid or CBDA( | + | Cannabidiolic-acid (CBDA) synthase is the enzyme that catalyzes the oxidative cyclization of cannabigerolic-acid(CBGA) into cannabidiolic acid or CBDA(Taura et.al, 2007). Cannabidiol (CBD) is a non-psychotropic constituent of the fiber-type cannabis plant which can be found in CBD oil, and it is obtained from non-enzymatic decarboxylation of CBDA (Takeda et.al, 2012). It is important to produce the CBGA to CBDA pathway synthetically independent of cannabis plants in order to insure the creation of CBD and not psychoactive tetrahydrocannabinol (THC). This is important because CBD oil can be used as an effective form of treatment for various disorders such as: seizures, cancer, anxiety, post-traumatic stress disorder, and Crohn’s disease.Since the CBDA synthase is 83.9% similar to THCA synthase in its 544-amino acid overlap, it should be possible to synthesize CBDA synthase in a similar fashion to THCA synthase which has been synthesized multiple times(Taura et.al, 2007). |
<br> | <br> | ||
<br> | <br> | ||
===References=== | ===References=== | ||
<p style="margin-left: 24pt; text-indent: -24pt;"><span | <p style="margin-left: 24pt; text-indent: -24pt;"><span | ||
− | lang="EN-US"> | + | lang="EN-US"> |
Takeda, S., Okajima, S., Miyoshi, H., Yoshida, K., Okamoto, Y., Okada, T., ... & Aramaki, H. (2012). Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicology letters, 214(3), 314-319.</span></p> | Takeda, S., Okajima, S., Miyoshi, H., Yoshida, K., Okamoto, Y., Okada, T., ... & Aramaki, H. (2012). Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicology letters, 214(3), 314-319.</span></p> | ||
+ | <p style="margin-left: 24pt; text-indent: -24pt;"><span | ||
+ | lang="EN-US">Taura, Futoshi, Supaart Sirikantaramas, Yoshinari Shoyama, Kazuyoshi Yoshikai, Yukihiro Shoyama, and Satoshi Morimoto. "Cannabidiolic‐acid synthase, the chemotype‐determining enzyme in the fiber‐type Cannabis sativa." FEBS letters 581, no. 16 (2007): 2929-2934..</span></p> | ||
+ | |||
+ | |||
===Usage and Biology=== | ===Usage and Biology=== | ||
+ | |||
+ | CBDA Synthase does not activate cannabinoid receptors (CB1 and CB2) and it has shown promise in treating many diseases or conditions such as: seizures, cancer, anxiety, pain, and many others. Since the CBDA synthase is 83.9% similar to THCA synthase in its 544-amino acid overlap, the synthesis of CBDA synthase should be similar to THCA synthase (Futoshi et.al, 2007). | ||
<!-- --> | <!-- --> |
Latest revision as of 15:23, 29 October 2016
CBDA Synthase
Cannabidiolic-acid (CBDA) synthase is the enzyme that catalyzes the oxidative cyclization of cannabigerolic-acid(CBGA) into cannabidiolic acid or CBDA(Taura et.al, 2007). Cannabidiol (CBD) is a non-psychotropic constituent of the fiber-type cannabis plant which can be found in CBD oil, and it is obtained from non-enzymatic decarboxylation of CBDA (Takeda et.al, 2012). It is important to produce the CBGA to CBDA pathway synthetically independent of cannabis plants in order to insure the creation of CBD and not psychoactive tetrahydrocannabinol (THC). This is important because CBD oil can be used as an effective form of treatment for various disorders such as: seizures, cancer, anxiety, post-traumatic stress disorder, and Crohn’s disease.Since the CBDA synthase is 83.9% similar to THCA synthase in its 544-amino acid overlap, it should be possible to synthesize CBDA synthase in a similar fashion to THCA synthase which has been synthesized multiple times(Taura et.al, 2007).
References
Takeda, S., Okajima, S., Miyoshi, H., Yoshida, K., Okamoto, Y., Okada, T., ... & Aramaki, H. (2012). Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicology letters, 214(3), 314-319.
Taura, Futoshi, Supaart Sirikantaramas, Yoshinari Shoyama, Kazuyoshi Yoshikai, Yukihiro Shoyama, and Satoshi Morimoto. "Cannabidiolic‐acid synthase, the chemotype‐determining enzyme in the fiber‐type Cannabis sativa." FEBS letters 581, no. 16 (2007): 2929-2934..
Usage and Biology
CBDA Synthase does not activate cannabinoid receptors (CB1 and CB2) and it has shown promise in treating many diseases or conditions such as: seizures, cancer, anxiety, pain, and many others. Since the CBDA synthase is 83.9% similar to THCA synthase in its 544-amino acid overlap, the synthesis of CBDA synthase should be similar to THCA synthase (Futoshi et.al, 2007).
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 1271
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 541
Illegal NgoMIV site found at 1120 - 1000COMPATIBLE WITH RFC[1000]